IL13RA2
| IL13RA2 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Identifiers | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Aliases | IL13RA2, CD213A2, CT19, IL-13R, IL13BP, interleukin 13 receptor subunit alpha 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| External IDs | OMIM: 300130; MGI: 1277954; GeneCards: IL13RA2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Wikidata | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interleukin-13 receptor subunit alpha-2 (IL-13Rα2), also known as CD213A2 (cluster of differentiation 213A2), is a membrane bound protein that in humans is encoded by the IL13RA2 gene.[5]
Function
[edit]IL-13Rα2 is closely related to IL-13Rα1, a subunit of the interleukin-13 receptor complex. This protein binds IL13 with high affinity, but lacks any significant cytoplasmic domain, and does not appear to function as a signal mediator. It is, however, able to regulate the effects of both IL-13 and IL-4, despite the fact it is unable to bind directly to the latter. It is also reported to play a role in the internalization of IL13.[5]
IL-13Rα2 was initially considered a “decoy receptor” because its short intracellular domain and lack of a conventional JAK/STAT signaling motif suggested that it primarily functioned by binding and sequestering IL-13 without initiating downstream signaling. However, subsequent studies have demonstrated that IL-13Rα2 can activate distinct signaling pathways, including AP-1 and TGF-β production. These findings have established a more active role for IL-13Rα2 in cancer biology, where it has been implicated in tumor proliferation, invasion, and metastasis..[6]
Clinical significance
[edit]IL-13Rα2 has been found to be over-expressed in a variety of cancers, including pancreatic, ovarian, melanomas, and malignant gliomas.[7][8][9][10]
See also
[edit]References
[edit]- 1 2 3 GRCh38: Ensembl release 89: ENSG00000123496 – Ensembl, May 2017
- 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000031289 – Ensembl, May 2017
- ↑ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ↑ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- 1 2 "Entrez Gene: IL13RA2 interleukin 13 receptor, alpha 2".
- ↑ Knudson KM, Hwang S, McCann MS, Joshi BH, Husain SR, Puri RK (2022). "Recent Advances in IL-13Rα2-Directed Cancer Immunotherapy". Frontiers in Immunology. 13 878365. doi:10.3389/fimmu.2022.878365. PMC 9023787. PMID 35464460.
- ↑ Fujisawa T, Joshi B, Nakajima A, Puri RK (November 2009). "A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis". Cancer Research. 69 (22): 8678–8685. doi:10.1158/0008-5472.CAN-09-2100. PMID 19887609.
- ↑ Kioi M, Kawakami M, Shimamura T, Husain SR, Puri RK (September 2006). "Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy". Cancer. 107 (6): 1407–1418. doi:10.1002/cncr.22134. PMID 16902988. S2CID 70773746.
- ↑ Okamoto H, Yoshimatsu Y, Tomizawa T, Kunita A, Takayama R, Morikawa T, et al. (February 2019). "Interleukin-13 receptor α2 is a novel marker and potential therapeutic target for human melanoma". Scientific Reports. 9 (1) 1281. Bibcode:2019NatSR...9.1281O. doi:10.1038/s41598-019-39018-3. PMC 6362032. PMID 30718742.
- ↑ Joshi BH, Plautz GE, Puri RK (March 2000). "Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas". Cancer Research. 60 (5): 1168–1172. PMID 10728667.
Further reading
[edit]- Andrews AL, Nasir T, Bucchieri F, Holloway JW, Holgate ST, Davies DE (October 2006). "IL-13 receptor alpha 2: a regulator of IL-13 and IL-4 signal transduction in primary human fibroblasts". The Journal of Allergy and Clinical Immunology. 118 (4): 858–865. doi:10.1016/j.jaci.2006.06.041. PMID 17030238.
- Caput D, Laurent P, Kaghad M, Lelias JM, Lefort S, Vita N, et al. (July 1996). "Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor alpha chain". The Journal of Biological Chemistry. 271 (28): 16921–16926. doi:10.1074/jbc.271.28.16921. PMID 8663118.
- Zhang JG, Hilton DJ, Willson TA, McFarlane C, Roberts BA, Moritz RL, et al. (April 1997). "Identification, purification, and characterization of a soluble interleukin (IL)-13-binding protein. Evidence that it is distinct from the cloned Il-13 receptor and Il-4 receptor alpha-chains". The Journal of Biological Chemistry. 272 (14): 9474–9480. doi:10.1074/jbc.272.14.9474. PMID 9083087.
- Gauchat JF, Schlagenhauf E, Feng NP, Moser R, Yamage M, Jeannin P, et al. (April 1997). "A novel 4-kb interleukin-13 receptor alpha mRNA expressed in human B, T, and endothelial cells encoding an alternate type-II interleukin-4/interleukin-13 receptor". European Journal of Immunology. 27 (4): 971–978. doi:10.1002/eji.1830270425. PMID 9130652. S2CID 23762963.
- Guo J, Apiou F, Mellerin MP, Lebeau B, Jacques Y, Minvielle S (May 1997). "Chromosome mapping and expression of the human interleukin-13 receptor". Genomics. 42 (1): 141–145. doi:10.1006/geno.1997.4628. PMID 9177784.
- Donaldson DD, Whitters MJ, Fitz LJ, Neben TY, Finnerty H, Henderson SL, et al. (September 1998). "The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1". Journal of Immunology. 161 (5). Baltimore: 2317–2324. doi:10.4049/jimmunol.161.5.2317. PMID 9725226. S2CID 255357984.
- Osawa M, Miyoshi S, Copeland NG, Gilbert DJ, Jenkins NA, Hiroyama T, et al. (September 2000). "Characterization of the mouse interleukin-13 receptor alpha1 gene". Immunogenetics. 51 (11): 974–981. doi:10.1007/s002510000225. PMID 11003391. S2CID 9030454.
- Kawakami K, Takeshita F, Puri RK (July 2001). "Identification of distinct roles for a dileucine and a tyrosine internalization motif in the interleukin (IL)-13 binding component IL-13 receptor alpha 2 chain". The Journal of Biological Chemistry. 276 (27): 25114–25120. doi:10.1074/jbc.M100936200. PMID 11352909.
- Daines MO, Hershey GK (March 2002). "A novel mechanism by which interferon-gamma can regulate interleukin (IL)-13 responses. Evidence for intracellular stores of IL-13 receptor alpha -2 and their rapid mobilization by interferon-gamma". The Journal of Biological Chemistry. 277 (12): 10387–10393. doi:10.1074/jbc.M108109200. PMID 11786536.
- Okano F, Storkus WJ, Chambers WH, Pollack IF, Okada H (September 2002). "Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain". Clinical Cancer Research. 8 (9): 2851–2855. PMID 12231526.
- Cancino-Díaz JC, Reyes-Maldonado E, Bañuelos-Pánuco CA, Jiménez-Zamudio L, García-Latorre E, León-Dorantes G, et al. (November 2002). "Interleukin-13 receptor in psoriatic keratinocytes: overexpression of the mRNA and underexpression of the protein". The Journal of Investigative Dermatology. 119 (5): 1114–1120. doi:10.1046/j.1523-1747.2002.19509.x. PMID 12445201.
- David M, Bertoglio J, Pierre J (November 2002). "TNF-alpha potentiates IL-4/IL-13-induced IL-13Ralpha2 expression". Annals of the New York Academy of Sciences. 973 (1): 207–209. Bibcode:2002NYASA.973..207D. doi:10.1111/j.1749-6632.2002.tb04633.x. PMID 12485861. S2CID 86154739.
- Wu AH, Low WC (July 2003). "Molecular cloning and identification of the human interleukin 13 alpha 2 receptor (IL-13Ra2) promoter". Neuro-Oncology. 5 (3): 179–187. doi:10.1215/s1152851702000510. PMC 1920687. PMID 12816724.
- Arima K, Sato K, Tanaka G, Kanaji S, Terada T, Honjo E, et al. (July 2005). "Characterization of the interaction between interleukin-13 and interleukin-13 receptors". The Journal of Biological Chemistry. 280 (26): 24915–24922. doi:10.1074/jbc.M502571200. PMID 15870068.
- Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A (January 2006). "IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis". Nature Medicine. 12 (1): 99–106. doi:10.1038/nm1332. PMID 16327802. S2CID 38397076.
- Daines MO, Tabata Y, Walker BA, Chen W, Warrier MR, Basu S, et al. (June 2006). "Level of expression of IL-13R alpha 2 impacts receptor distribution and IL-13 signaling". Journal of Immunology. 176 (12). Baltimore: 7495–7501. doi:10.4049/jimmunol.176.12.7495. PMID 16751396.
- Granel B, Allanore Y, Chevillard C, Arnaud V, Marquet S, Weiller PJ, et al. (October 2006). "IL13RA2 gene polymorphisms are associated with systemic sclerosis". The Journal of Rheumatology. 33 (10): 2015–2019. PMID 16981293.
External links
[edit]- IL13RA2+protein,+human at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
- Overview of all the structural information available in the PDB for UniProt: Q14627 (Interleukin-13 receptor subunit alpha-2) at the PDBe-KB.
This article incorporates text from the United States National Library of Medicine, which is in the public domain.
| 1–50 | |
|---|---|
| 51–100 | |
| 101–150 | |
| 151–200 | |
| 201–250 | |
| 251–300 | |
| 301–350 | |
| 351–371 | |
 | This membrane protein–related article is a stub. You can help Wikipedia by adding missing information. |